Lunai Bioworks (LNAI)
Biomedical-AI analytics and zebrafish screening for preclinical discovery.
Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit
Second Amended Complaint Alleges Securities Fraud and Market Manipulation Under Rule 10b-5 WILMINGTON, Del. and SACRAMENTO, Calif.
Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027
New BioSymetrics Inc. white paper and executed Master Collaboration Agreement establish an integrated roadmap spanning AI-driven patient stratification, human translational validation, biomarker development, and pharmaceutical partnering. SACRAMENTO, Calif.
Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit
Amended Complaint Alleges 29.6 Million Failed to Deliver Shares and Single Day Trading Volume of 15.3 Times Shares Outstanding, Company Seeks Treble Damages Under Federal RICO Statute WILMINGTON, Del. and SACRAMENTO, Calif.
LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS
SACRAMENTO, Calif., June 17, 2026 /PRNewswire/ -- Fellow Shareholders, Over the past several months, Lunai Bioworks (NASDAQ: LNAI) has continued to execute its strategy of building a next-generation biotechnology company at the intersection of artificial intelligence, and national security and biology.
Lunai Bioworks (LNAI) Stock Is Trending Overnight — Here's Why It Spiked Nearly 81% In After-Hours Session
Lunai Bioworks Inc. shares soared 80.88% after-hours after regaining Nasdaq compliance with minimum bid price requirements.
Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration
Collaboration integrates AI discovery, human brain organoid modeling, and in vivo validation to generate differentiated neurology assets for pharmaceutical partnering and development SACRAMENTO, Calif. and SAN DIEGO, May 28, 2026 /PRNewswire/ -- Lunai Bioworks' (NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter of Intent (LOI) to jointly discover, validate, and advance novel therapeutic targets for neurological diseases.
Federal Judge Orders Expedited Discovery to Identify 'John Doe' Defendants 'Naked' Short-Sellers of Lunai Common Stock
WASHINGTON, May 22, 2026 /PRNewswire/ -- On Wednesday, May 20, 2026, a United States District Court Magistrate Judge in Delaware granted the Motion of Lunai Bioworks, Inc. (Nasdaq: LNAI) (Lunai) to conduct expedited discovery to identify the "John Doe" "naked" short sellers of Lunai common stock on the Nasdaq Stock Market in late 2025 and throughout the first half of 2026. Co-lead counsel, Jacob Frenkel, Securities Enforcement Practice Chair at Dickinson Wright, stated: "This is the first step to amending the Complaint and holding accountable and pursuing substantial damages from the 'naked' short sellers who have caused real market harm to Lunai and its shareholders.
Dickinson Wright and Fox Rothschild Join Forces to File Lawsuit Against ‘John Doe’ ‘Naked’ Short-Sellers of Lunai Common Stock
WASHINGTON, D. C. , May 12, 2026 (GLOBE NEWSWIRE) -- via IBN -- On Monday, May 11, 2026, national law firms Dickinson Wright and Fox Rothschild joined forces to file a lawsuit on behalf of their firms' client, Lunai Bioworks, Inc. (Nasdaq: LNAI) (Lunai), alleging securities fraud (stock manipulation) and intentional tort against "John Doe" "naked" short sellers of Lunai common stock on the Nasdaq Stock Market.
Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships
Collaboration converts patient-led data into trial-ready cohorts to support drug development, commercial partnerships, and revenue-generating opportunities. Initial programs underway to integrate rare disease datasets and advance commercial partnership opportunities with pharmaceutical companies.
Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion
Advancing AI-enabled chemical threat detection and dual-use biodefense technologies through initial commercial deployment SACRAMENTO, Calif., April 7, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ: LNAI), an AI-driven drug discovery and biodefense company, today announced that its subsidiary, BioSymetrics, has entered into a revenue-generating, commercial defense-focused collaboration with a specialized biotechnology partner to support the development of an advanced AI-enabled platform for chemical threat assessment, with initial engagement underway and additional engagements currently under discussion.
Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model
AI platform integrates academic and defense research to accelerate rapid antidote discovery and federal stockpiling for emerging chemical threats. SACRAMENTO, Calif.
Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping
Foundational Patent Strengthens AI Moat Across Multimodal Data Standardization, Disease Stratification and Gene Mapping SACRAMENTO, Calif., Feb. 19, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ: LNAI), an AI-driven biotechnology company advancing precision therapeutics in central nervous system (CNS) disorders and oncology, as well as solutions for biodefense, today announced the issuance of U.S. Patent No.
Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC
SACRAMENTO, Calif., Feb. 13, 2026 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered biotech and biodefense company, was featured on CNBC's Business Minute.
Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data
AI-driven analysis of Phase 2 survival and progression data aims to identify high-benefit patient subgroups and optimize future registrational trial strategy SACRAMENTO, Calif., Feb. 9, 2026 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, today announced the launch of a new oncology collaboration with a clinical-stage partner to analyze data from a randomized Phase 2 metastatic colorectal cancer trial.
Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons
Transformer-based biosecurity layer embeds directly into foundation models, using Lunai's proprietary toxicology and in-vivo datasets to detect and prevent creation of previously unknown threat agents in real time . SACRAMENTO, Calif.
Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery
AI Platform Achieves Key Milestones, Triggering Launch of Alcohol Use Disorder Program SACRAMENTO, Calif. , Jan. 26, 2026 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, today announced it has completed a key commercial milestone under its NIH STTR-supported initiative, generating high-resolution, multidimensional behavioral signatures of ethanol exposure and alcohol withdrawal.
Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance
AI-powered drug discovery and biodefense company engages pharma on CNS programs amid rising deal activity SACRAMENTO, Calif. , Dec. 18, 2025 /PRNewswire/ -- Lunai Bioworks Inc. (NASDAQ: LNAI), an AI-driven pharmaceutical discovery company, was featured in International Business Times in a year-end analysis highlighting the company's strategic positioning, active partnership discussions, and favorable market dynamics as 2025 draws to a close.
Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market
SACRAMENTO, Calif. , Dec. 9, 2025 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered biotechnology company developing precision therapeutics, today announced the identification of three clinically relevant Parkinson's disease subtypes and prioritized drug targets that may accelerate proof-of-concept programs, derisk therapeutic development, and enable strategic co-development partnerships in a growing $13 billion market.
Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models
Following peer-reviewed publication and independent expert review of findings, the LOI advances Lunai's tumor-regressing immune-cell platform toward scalable therapies for aggressive cancers SACRAMENTO, Calif. , Nov. 25, 2025 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, today announced it has secured its first Letter of Intent (LOI) to license its next-generation immune cell therapy, which achieved complete regression of both primary and metastatic pancreatic tumors with no recurrence in humanized preclinical models.
Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy
/PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, has announced a major scientific breakthrough: its